CirCode Biomed
Suzhou, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Developing next-generation RNA therapeutics and vaccines using innovative circular RNA and other RNA technology platforms.
Infectious DiseaseOncologyGenetics & Genomics
Technology Platform
Proprietary circular RNA (circRNA) platform for designing stable, long-lasting RNA constructs, coupled with advanced delivery formulations like LNPs.
Opportunities
CircRNA technology has the potential to unlock new therapeutic applications requiring sustained protein expression, beyond the reach of current mRNA drugs.
Risk Factors
Unproven clinical efficacy and safety of the circRNA platform, alongside potential intellectual property disputes in a crowded space.
Competitive Landscape
Competes in the hotly contested RNA field against well-funded linear mRNA companies and other circRNA startups, requiring proof of superior platform performance.